NASDAQ:XCUR Exicure (XCUR) Stock Price, News & Analysis → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free XCUR Stock Alerts $0.54 +0.00 (+0.11%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$0.53▼$0.5550-Day Range$0.54▼$0.7452-Week Range$0.36▼$1.50Volume6,000 shsAverage Volume391,852 shsMarket Capitalization$4.67 millionP/E Ratio0.32Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Exicure alerts: Email Address Exicure MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.40% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment0.46Based on 2 Articles This WeekInsider TradingSelling Shares$4.49 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.74 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Exicure. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.40% of the float of Exicure has been sold short.Short Interest Ratio / Days to CoverExicure has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exicure has recently decreased by 1.53%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldExicure does not currently pay a dividend.Dividend GrowthExicure does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExicure has received a 74.39% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for mental health", "Clinical research services for cancer", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Exicure is -0.67. Previous Next 1.9 News and Social Media Coverage News SentimentExicure has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Exicure this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exicure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,488,000.00 in company stock.Percentage Held by InsidersOnly 8.40% of the stock of Exicure is held by insiders.Percentage Held by Institutions42.82% of the stock of Exicure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Exicure is 0.33, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.17.Price to Earnings Ratio vs. SectorThe P/E ratio of Exicure is 0.33, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 180.20.Price to Book Value per Share RatioExicure has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Exicure Stock (NASDAQ:XCUR)Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.Read More XCUR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XCUR Stock News HeadlinesApril 22, 2024 | businesswire.comExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-KApril 18, 2024 | americanbankingnews.comExicure (NASDAQ:XCUR) Shares Down 8.7% April 23, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...February 22, 2024 | benzinga.comExicure Stock (NASDAQ:XCUR), Short Interest ReportFebruary 6, 2024 | benzinga.comWhy FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionFebruary 6, 2024 | msn.comWhy Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving PremarketFebruary 6, 2024 | msn.comExicure Inc Announces Licensing Patents for Therapeutic AdvancementFebruary 5, 2024 | marketwatch.comExicure, Bluejay Therapeutics Enter Patent License Agreement to Develop Hepatitis TreatmentApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.February 5, 2024 | finance.yahoo.comExicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of HepatitisFebruary 1, 2024 | msn.comBest Undervalued Stocks for February 2024December 16, 2023 | ca.finance.yahoo.comExicure, Inc. (XCUR) Stock Price, News, Quote & History - Yahoo FinanceDecember 8, 2023 | investorplace.comWhy Is Exicure (XCUR) Stock Up 57% Today?November 28, 2023 | msn.comExicure receives Nasdaq delinquency notice on late filing of its form 10-QNovember 9, 2023 | morningstar.comExicure Inc XCURAugust 29, 2023 | finance.yahoo.comLacklustre Performance Is Driving Exicure, Inc.'s (NASDAQ:XCUR) 25% Price DropAugust 23, 2023 | msn.comExicure names new CEO, CFO, directors in wake of resignationsAugust 15, 2023 | finance.yahoo.comExicure First Half 2023 Earnings: US$1.38 loss per share (vs US$3.71 loss in 1H 2022)August 11, 2023 | marketwatch.comExicure: Substantial Financing Needed to Continue OperationsAugust 11, 2023 | businesswire.comExicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 14, 2023 | finance.yahoo.comExicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 26, 2023 | msn.comExicure board backs CEO Kim's strategic alternative view for companyMay 26, 2023 | finance.yahoo.comExicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic AlternativesMay 25, 2023 | sg.finance.yahoo.comExicure, Inc. (XCUR) stock price, news, quote & history – Yahoo FinanceMay 19, 2023 | seekingalpha.comExicure gets Nasdaq non-compliance notice for not filing 10-QApril 27, 2023 | finance.yahoo.comExicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of DirectorsMarch 28, 2023 | wsj.comExicure Warns of Need to Raise Additional Funds to Keep OperatingSee More Headlines Receive XCUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exicure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/19/2021Today4/23/2024Next Earnings (Estimated)7/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XCUR CUSIPN/A CIK1698530 Webwww.exicuretx.com Phone(847) 673-1700FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.32 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$28.83 million Price / Sales0.16 Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / Book0.18Miscellaneous Outstanding Shares8,650,000Free Float7,922,000Market Cap$4.67 million OptionableNot Optionable Beta1.31 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Paul Kang (Age 62)CEO & Director Ms. Jiyoung Hwang (Age 47)CFO & Director Mr. Joshua Miller (Age 48)Chief Accounting Officer Mr. Bart AndersonSenior Director of R&DKey CompetitorsAlzamend NeuroNASDAQ:ALZNOragenicsNYSE:OGENSeelos TherapeuticsNASDAQ:SEELKinetaNASDAQ:KASonnet BioTherapeuticsNASDAQ:SONNView All CompetitorsInsidersCo. Ltd. DgpSold 3,400,000 sharesTotal: $4.49 M ($1.32/share)View All Insider Transactions XCUR Stock Analysis - Frequently Asked Questions How have XCUR shares performed in 2024? Exicure's stock was trading at $0.5803 at the beginning of 2024. Since then, XCUR shares have decreased by 5.8% and is now trading at $0.5464. View the best growth stocks for 2024 here. When is Exicure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, July 12th 2024. View our XCUR earnings forecast. How were Exicure's earnings last quarter? Exicure, Inc. (NASDAQ:XCUR) announced its quarterly earnings results on Friday, November, 19th. The company reported ($8.10) EPS for the quarter, missing the consensus estimate of ($2.70) by $5.40. The business had revenue of ($3.68) million for the quarter, compared to the consensus estimate of $0.80 million. When did Exicure's stock split? Exicure's stock reverse split on Thursday, June 30th 2022. The 1-30 reverse split was announced on Thursday, June 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Exicure? Shares of XCUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XCUR) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersIs Tesla going out of business?DTI Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
